Table 4.
Principal component analysis of serum biomarkers in ankylosing spondylitis patients at baseline
| PC1 | PC2 | PC3 | PC4 | PC5 | PC6 | PC7 | PC8 |
|---|---|---|---|---|---|---|---|
| IL-15 (0.972) | IFNγ (0.955) | MMP-8 (0.849) | GM-CSF (0.913) | CXCL10 (-0.676) | MMP-2 (-0.700) | bFGF (0.744) | EGF (0.735) |
| IL-2 (0.970) | IL-12 (0.936) | MMP-9 (0.796) | IL-10 (0.813) | IL-13 (0.626) | MMP-3 (-0.759) | IL-1Ra (0.493) | CXCL8 (0.436) |
| MIP-1β (0.930) | IL-5 (0.842) | CXCL8 (0.527) | VEGF (0.437) | MCP-1 (0.425) | |||
| IFNα (0.916) | Eotaxin (0.760) | HGF (0.453) | |||||
| IL-1β (0.877) | IL-2R (0.712) | ||||||
| TNFα (0.841) | IL-17 (0.633) | ||||||
| MIP-1α (0.812) | IL-4 (-0.565) | ||||||
| IL-7 (0.771) | IL-13 (0.525) | ||||||
| IL-6 (0.736) | MCP-1 (0.499) | ||||||
| MIG (0.722) | VEGF (-0.477) | ||||||
| IL-1Ra (0.680) | TNFα (0.408) | ||||||
| IL-17 (0.674) | |||||||
| IL-4 (0.673) | |||||||
| IL-2R (0.609) | |||||||
| GCSF (0.486) | |||||||
| HGF (0.462) | |||||||
| 30.16%a | 17.61%a | 6.63%a | 6.03%a | 4.80%a | 3.90%a | 4.70%a | 4.44%a |
Biomarkers in each principal component are shown with factor loadings (brackets) after varimax rotation. bFGF, basic fibroblast growth factor; EGF, epidermal growth factor; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; HGF, hepatocyte growth factor; IL-1Ra, IL-1 receptor antagonist; MCP-1, monocyte chemotactic protein-1; MIG, monokine induced by gamma interferon; MIP-1, macrophage inflammatory protein-1; MMP, matrix metalloproteinase; PC, principal component; VEGF, vascular endothelial growth factor. aPercentage variance.